Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OP
– Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company’s work to advance STK-002 as the first potential disease modifying treatment for Autosomal Dominant Optic Atrophy (ADOA) –– ADOA is the most common inherited optic nerve disorder –BEDFORD, Mass.--(B...
Source: pharmiweb.com